---
search:
  boost: .9
---

# Endocrine Agents - Diabetes – Non-Insulin

[Criteria Document](https://mygainwell-my.sharepoint.com/:w:/g/personal/kaelyn_dobbins_gainwelltechnologies_com/ERZFf5L5Pm9PuMVZLt1_oRcBmaYvEZk_YbBzDdpDKlP6Aw?e=FTExkT){:target="_blank" rel="noopener}

|||
| ---------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Criteria 1 | NP Agents- Adlyxin, Alogliptin, Bydureon Bcise, Glucophage, Metformin ER (Generic of Fortamet, Glumetza), Metformin Sol, Mounjaro, Onglyza, Ozempic, Rybelsus, Steglatro, Symlinpen                                                                 |
| Criteria 2 | NP Agents – Combination Agents- Alogliptin/Metformin, Glimepiride/Pioglitazone, Glyxambi, Invokamet XR, Jentadueto XR, Kombiglyze XR, Pioglitazone/Alogliptin, Qtern, Segluromet, Soliqua, Steglujan, Synjardy XR, Trijardy XR, Xigduo XR, Xultophy |

   

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Endocrine Agents: Diabetes – Non-Insulin</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>ADLYXIN</td>
<td>071734</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADLYXIN</td>
<td>071735</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALOGLIPTIN</td>
<td>070517</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALOGLIPTIN</td>
<td>070524</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALOGLIPTIN</td>
<td>070525</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>BYDUREON BCISE</td>
<td>077890</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>GLUCOPHAGE</td>
<td>013318</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>GLUCOPHAGE</td>
<td>016441</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>GLUCOPHAGE</td>
<td>040974</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>GLUCOPHAGE</td>
<td>046754</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>GLUCOPHAGE</td>
<td>052080</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>METFORMIN ER (Gen of Fortamet)</td>
<td>061267</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>METFORMIN ER (Gen of Fortamet)</td>
<td>061273</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>METFORMIN ER (Gen of Fortamet)</td>
<td>054018</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>METFORMIN ER (Gen of Fortamet)</td>
<td>054019</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>METFORMIN ER (Gen of Glumetza)</td>
<td>061267</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>METFORMIN ER (Gen of Glumetza)</td>
<td>061273</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>METFORMIN SOL</td>
<td>053351</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>METFORMIN SOL</td>
<td>080166</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>MOUNJARO</td>
<td>083388</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>MOUNJARO</td>
<td>083389</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>MOUNJARO</td>
<td>083390</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>MOUNJARO</td>
<td>083391</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>MOUNJARO</td>
<td>083392</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>MOUNJARO</td>
<td>083393</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ONGLYZA</td>
<td>065430</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ONGLYZA</td>
<td>065431</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>OZEMPIC</td>
<td>077985</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>OZEMPIC</td>
<td>077986</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>OZEMPIC</td>
<td>081168</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>OZEMPIC</td>
<td>083225</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RYBELSUS</td>
<td>080228</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>RYBELSUS</td>
<td>080229</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RYBELSUS</td>
<td>080230</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>STEGLATRO</td>
<td>078041</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>STEGLATRO</td>
<td>078042</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SYMLINPEN</td>
<td>063735</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SYMLINPEN</td>
<td>063804</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">120 days</span> with at least <span class="underline">three preferred drugs</span>?</p>
<p>If yes, please submit the medication trials and dates.</p>
<p>Please note: For non-preferred drugs that have preferred drugs in the same drug class: must provide documentation that there was at least <span class="underline">one</span> inadequate clinical response with a drug in same drug class.</p>
<p>Please note: An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.  </p></td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1002</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Does the patient have a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1005</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1005</td>
<td></td>
<td>Select </td>
<td>Is the request for Metformin ER (Generic of Fortamet, Glumetza)?</td>
<td>Y</td>
<td>1006</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1006</td>
<td></td>
<td>Select </td>
<td>What strength is being requested?</td>
<td>Metformin HCl SR Tab 500 MG</td>
<td>1007</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Metformin HCl SR Tab (<strong><span class="underline">all strengths excluding 500 MG</span></strong>)</td>
<td>1008</td>
</tr>
<tr class="odd">
<td>10</td>
<td>1007</td>
<td></td>
<td>Select  </td>
<td>Ohio Medicaid covers up to 408 tablets per 102 days. Does this request meet this requirement?</td>
<td>Y</td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1237</td>
</tr>
<tr class="odd">
<td>11</td>
<td>1008</td>
<td></td>
<td>Select  </td>
<td>Ohio Medicaid covers up to 204 tablets per 102 days. Does this request meet this requirement?</td>
<td>Y</td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1237</td>
</tr>
<tr class="odd">
<td>12</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td> Y    </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>13</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>14</td>
<td>1237</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the dose and frequency being requested.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days 

| **Last Approved ** | 5/18/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Endocrine Agents: Diabetes – Non-Insulin</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred Combination Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>ALOGLIPTIN/METFORMIN</td>
<td>070526</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALOGLIPTIN/METFORMIN</td>
<td>070527</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>GLIMEPIRIDE/PIOGLITAZONE</td>
<td>061388</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>GLIMEPIRIDE/PIOGLITAZONE</td>
<td>061389</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>GLYXAMBI</td>
<td>073432</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>GLYXAMBI</td>
<td>073433</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>INVOKAMET XR</td>
<td>076620</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>INVOKAMET XR</td>
<td>076621</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>INVOKAMET XR</td>
<td>076622</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>INVOKAMET XR</td>
<td>076623</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>JENTADUETO XR</td>
<td>076256</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>JENTADUETO XR</td>
<td>076257</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>KOMBIGLYZE XR</td>
<td>066816</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>KOMBIGLYZE XR</td>
<td>066817</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>KOMBIGLYZE XR</td>
<td>066818</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>PIOGLITAZONE/ALOGLIPTIN</td>
<td>070518</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>PIOGLITAZONE/ALOGLIPTIN</td>
<td>070519</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>PIOGLITAZONE/ALOGLIPTIN</td>
<td>070520</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>PIOGLITAZONE/ALOGLIPTIN</td>
<td>070522</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>QTERN</td>
<td>077192</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>QTERN</td>
<td>079873</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SEGLUROMET</td>
<td>078051</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SEGLUROMET</td>
<td>078052</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SEGLUROMET</td>
<td>078053</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SEGLUROMET</td>
<td>078054</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SOLIQUA</td>
<td>076864</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>STEGLUJAN</td>
<td>078036</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>STEGLUJAN</td>
<td>078037</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SYNJARDY XR</td>
<td>076940</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SYNJARDY XR</td>
<td>076941</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SYNJARDY XR</td>
<td>076942</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SYNJARDY XR</td>
<td>076943</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TRIJARDY XR</td>
<td>080710</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TRIJARDY XR</td>
<td>080711</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TRIJARDY XR</td>
<td>080712</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TRIJARDY XR</td>
<td>080713</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>XIGDUO XR</td>
<td>073029</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>XIGDUO XR</td>
<td>073030</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>XIGDUO XR</td>
<td>073031</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>XIGDUO XR</td>
<td>073032</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>XIGDUO XR</td>
<td>078062</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>XULTOPHY</td>
<td>073919</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">120 days</span> with at least <span class="underline">three preferred drugs</span>?</p>
<p>If yes, please submit the medication trials and dates.</p>
<p>Please note: For non-preferred drugs that have preferred drugs in the same drug class: must provide documentation that there was at least <span class="underline">one</span> inadequate clinical response with a drug in same drug class.</p>
<p>Please note: An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.  </p></td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1002</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Does the patient have a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had a trial of at least <span class="underline">120 days</span> with the individual drugs?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1004</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for patient’s inability to use the individual drugs?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>8</td>
<td>1005</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1006</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1006</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>10</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td> Y    </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>11</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>12</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days 

| **Last Approved ** | 5/18/2023 |
| ------------------ | --------- |
| **Other**          |           |

Endocrine Agents: Diabetes-Non-Insulin

| Class                                             | Preferred Agents                                      | Non-Preferred Agents                                                    |
| ------------------------------------------------- | ----------------------------------------------------- | ----------------------------------------------------------------------- |
| Alpha-Glucosidase Inhibitor                       | Acarbose, Miglitol                                    |                                                                         |
| Amylinomimetic                                    |                                                       | Symlinpen                                                               |
| Biguanide                                         | Metformin IR, Metformin ER (Generic of Glucophage XR) | Glucophage, Metformin ER (Generic of Fortamet, Glumetza), Metformin Sol |
| Dipeptidyl Peptidase 4 (DPP-4) Inhibitor          | Januvia, Tradjenta                                    | Alogliptin, Onglyza                                                     |
| Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)  | Byetta, Trulicity, Victoza                            | Adlyxin, Bydureon Bcise, Mounjaro, Ozempic, Rybelsus                    |
| Meglitinide                                       | Nateglinide, Repaglinide                              |                                                                         |
| Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor | Farxiga, Invokana, Jardiance                          | Steglatro                                                               |
| Sulfonylurea                                      | Glimepiride, Glipizide, Glyburide                     |                                                                         |
| Thiazolidinedione                                 | Pioglitazone                                          |                                                                         |
| Combinations                                      |                                                       |                                                                         |
| Biguanide + DPP-4 Inhibitor                       | Janumet, Janumet XR, Jentadueto                       | Alogliptin/Metformin, Jentadueto XR, Kombiglyze XR                      |
| Biguanide + DPP-4 Inhibitor + SGLT-2 Inhibitor    |                                                       | Trijardy XR                                                             |
| Biguanide + Meglitinide                           | Repaglinide/Metformin                                 |                                                                         |
| Biguanide + SGLT-2 Inhibitor                      | Invokamet, Synjardy                                   | Invokamet XR, Segluromet, Synjardy XR, Xigduo XR                        |
| Biguanide + Sulfonylurea                          | Glipizide/Metformin, Glyburide/Metformin              |                                                                         |
| Biguanide + Thiazolidinedione                     | Actoplus Met XR, Pioglitazone/Metformin               |                                                                         |
| DPP-4 Inhibitor + SGLT-2 Inhibitor                |                                                       | Glyxambi, Qtern, Steglujan                                              |
| DPP-4 Inhibitor + Thiazolidinedione               |                                                       | Pioglitazone/Alogliptin                                                 |
| GLP-1 Receptor Agonist + Insulin                  |                                                       | Soliqua, Xultophy                                                       |
| Sulfonylurea + Thiazolidinedione                  |                                                       | Glimepiride/Pioglitazone                                                |
